Humane Genomics Analysis: $125K Raised
What is Humane Genomics?
Humane Genomics develops oncolytic therapies by engineering RNA viruses to selectively infect and destroy cancer cells. Its platform uses computer-aided design, DNA synthesis, and virus rescue workflows, with a stated emphasis on systemic delivery and selective replication. The company is advancing a lead candidate for hepatoblastoma and has moved toward cGMP manufacturing for preclinical and early clinical development.
Location
180 Varick Street, Floor 6, New York, NY 10014, US
Employees
1-10
Founded
2019
Revenue
$1.1-1.6M
Investors
- Union Square Ventures
Product Features & Capabilities
- RNA-based viral therapies, selective infection and replication, high lytic activity, >1000 on-target to off-target kill ratio, pediatric liver cancer (hepatoblastoma) treatment, in vivo safety data, 50% reduction in tumor volume.
How much Humane Genomics raised
1 - $125,000
September 1, 2021Lead Investor: Y Combinator
Who are the founders of Humane Genomics
PW
Peter Weijmarshausen
Founder
CM
Chad Moles
Founder
Competitors Overview
Humane Genomics operates in the field of cancer therapies, specifically focusing on engineered viruses to target and destroy cancer cells. Its main competitors include:
-
HelixNano: This company is developing next-generation mRNA technologies and cancer vaccines that augment the immune system's ability to fight disease. They are currently conducting Phase 1 clinical trials for their cancer vaccines targeting metastatic tumors. HelixNano's advantage lies in its focus on mRNA technology, which has gained significant attention for its potential in various therapeutic areas, including cancer.
-
METiS Therapeutics: This company is known for its Tumor Treating Fields (TTFields) technology, which uses electric fields to disrupt cancer cell division. The METIS trial demonstrated significant efficacy in extending the time to intracranial progression in patients with brain metastases. METiS's unique approach of using electric fields distinguishes it from traditional therapies, providing a non-invasive treatment option.
-
CureGenetics: A clinical-stage company focused on developing cell and gene therapies for solid tumors and genetic diseases. They utilize innovative platforms like AIMS CAR-NKT and VELPTM AAV to create a differentiated pipeline of therapies. CureGenetics' emphasis on gene therapy offers a distinct advantage in targeting the genetic basis of cancer, potentially leading to more personalized treatment options.
These competitors highlight different technological approaches in the cancer therapy market, with Humane Genomics focusing on engineered viruses, while others explore mRNA, electric fields, and gene therapies.
Market Focus
Humane Genomics primarily focuses on the biotechnology industry, specifically in the development of precision therapies that utilize engineered viruses to target and destroy cancer cells.
See something that needs updating? Suggest edits to this profile.